{"id":1590,"date":"2021-10-13T05:31:17","date_gmt":"2021-10-13T09:31:17","guid":{"rendered":"https:\/\/neoaptamers.com\/?p=1590"},"modified":"2026-04-14T09:33:03","modified_gmt":"2026-04-14T13:33:03","slug":"commercializing-aptamers-part-6","status":"publish","type":"post","link":"https:\/\/neoaptamers.com\/es\/commercializing-aptamers-part-6\/","title":{"rendered":"Commercializing Aptamers Part 6"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"1590\" class=\"elementor elementor-1590\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-dc692d0 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"dc692d0\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-835bb97\" data-id=\"835bb97\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-2ab70ee elementor-widget elementor-widget-text-editor\" data-id=\"2ab70ee\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><em>\u201cThe single biggest problem in communication is the illusion that it has taken place.\u201d George Bernard Shaw<\/em><\/p><p>In this blog, I am staying on the theme of commercialization of aptamers, leading up to our forthcoming webinar on aptamer commercialization on October 20<sup>th<\/sup>. The focus of this blog may be controversial, I am suggesting that one of the biggest constraints to commercialization of aptamers is the current nature of peer reviewed publications on aptamer applications.<\/p><p>The problem as I see it with peer reviewed publications on aptamer applications are as follows;<\/p><ul><li>Trying to replicate published results is extremely difficult due to a lack of sufficient information regarding protocols.<\/li><\/ul><p>There are many reasons for this. One, is that the material and methods sections of publications often resemble nested Russian dolls with references to references that may or may not actually contain the protocol.<\/p><p>Another difficulty is the difference in approach to the science behind a publication and the effort to replicate it. When replicating a scientific experiment, the question continually arises as to whether this particular experiment was valid or should be discarded. Science focused only on publication does not require dealing with specifications for every step. If the results do not look right, they can be ignored, that experiment can be ignored, and the process repeated. When replicating the experiment, or even worse trying to commercialize it, this option does not exist. There is a need to consider why the results from different experiments differ. We need to set specifications for every element such that an experimental result would be discarded on the basis of not meeting these specifications, not because the result does not match what we expect.<\/p><p>A third reason that publications are difficult to replicate is the aspect of time. The time between the formulation of an aptamer, formulation of buffers, solubilization of targets and the experiment being performed can affect the outcome. This crucial knowledge required for the replication of experiments is generally absent from publications. \u00a0<\/p><ul><li>Often results from peer-reviewed publications are not reproducible even if you follow everything that the authors did completely.<\/li><\/ul><p>I am not saying here that authors are lying about their data. We have had results in our laboratory that are tremendously exciting, but which we cannot replicate. Such results in our current peer-reviewed process can and often are published. A key difficulty is that scientific communication has ceased to be a conversation and become a commodity. Academic appointments are largely based on the number of publications that the applicant has, not the reproducibility of these publications. There is a constant proliferation of journals and conferences all aimed at making money out of scientific conversation. This has become a cacophony where talking scores points, listening does not.<\/p><p>I think that in our online age, the concept of peer-review is outdated. I think every scientist should simply be posting their results (after filing appropriate patents) on their websites along with appropriate and fully detailed protocols. Such postings should necessarily include and maintain comment threads by others who read the results and try to replicate them. Your reputation should be based on the reproducibility of your results within the\u00a0 community not by passing the gate of being merely read by two or three others.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>\u201cThe single biggest problem in communication is the illusion that it has taken place.\u201d George Bernard Shaw In this blog, I am staying on the theme of commercialization of aptamers, leading up to our forthcoming webinar on aptamer commercialization on October 20th. The focus of this blog may be controversial, I am suggesting that one&hellip;&nbsp;<a href=\"https:\/\/neoaptamers.com\/es\/commercializing-aptamers-part-6\/\" rel=\"bookmark\">Leer m\u00e1s &raquo;<span class=\"screen-reader-text\">Commercializing Aptamers Part 6<\/span><\/a><\/p>","protected":false},"author":1,"featured_media":1598,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"off","neve_meta_content_width":70,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[12],"tags":[],"class_list":["post-1590","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-aptamer-commercialization"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Commercializing Aptamers Part 6<\/title>\n<meta name=\"description\" content=\"Explore the challenges of commercializing aptamers in our thought-provoking blog, as we dare to tackle a controversial subject. Read now.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/neoaptamers.com\/es\/commercializing-aptamers-part-6\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Commercializing Aptamers Part 6\" \/>\n<meta property=\"og:description\" content=\"Explore the challenges of commercializing aptamers in our thought-provoking blog, as we dare to tackle a controversial subject. Read now.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/neoaptamers.com\/es\/commercializing-aptamers-part-6\/\" \/>\n<meta property=\"og:site_name\" content=\"neoaptamers\" \/>\n<meta property=\"article:published_time\" content=\"2021-10-13T09:31:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-14T13:33:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/neoaptamers.com\/wp-content\/uploads\/2021\/10\/zxzxx.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"partyinfrance\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"partyinfrance\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/commercializing-aptamers-part-6\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/commercializing-aptamers-part-6\\\/\"},\"author\":{\"name\":\"partyinfrance\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/person\\\/34934951075d3d931c9216ed7f568fe6\"},\"headline\":\"Commercializing Aptamers Part 6\",\"datePublished\":\"2021-10-13T09:31:17+00:00\",\"dateModified\":\"2026-04-14T13:33:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/commercializing-aptamers-part-6\\\/\"},\"wordCount\":542,\"publisher\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/commercializing-aptamers-part-6\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/zxzxx.png\",\"articleSection\":[\"Aptamer commercialization\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/commercializing-aptamers-part-6\\\/\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/commercializing-aptamers-part-6\\\/\",\"name\":\"Commercializing Aptamers Part 6\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/commercializing-aptamers-part-6\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/commercializing-aptamers-part-6\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/zxzxx.png\",\"datePublished\":\"2021-10-13T09:31:17+00:00\",\"dateModified\":\"2026-04-14T13:33:03+00:00\",\"description\":\"Explore the challenges of commercializing aptamers in our thought-provoking blog, as we dare to tackle a controversial subject. Read now.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/commercializing-aptamers-part-6\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/neoaptamers.com\\\/commercializing-aptamers-part-6\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/commercializing-aptamers-part-6\\\/#primaryimage\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/zxzxx.png\",\"contentUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/zxzxx.png\",\"width\":1200,\"height\":600,\"caption\":\"commercial aptamers part 6\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/commercializing-aptamers-part-6\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/neoaptamers.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Commercializing Aptamers Part 6\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#website\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/\",\"name\":\"Neoaptamers.com\",\"description\":\"Neoventures Biotechnology Inc.\",\"publisher\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/neoaptamers.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\",\"name\":\"NeoVentures Biotechnology Inc.\",\"alternateName\":\"NVB\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png\",\"contentUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png\",\"width\":500,\"height\":500,\"caption\":\"NeoVentures Biotechnology Inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/neoventures-biotechnology-inc-\\\/\",\"https:\\\/\\\/www.reddit.com\\\/user\\\/NeoVenturesBiotech\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@neoaptamers7964\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/person\\\/34934951075d3d931c9216ed7f568fe6\",\"name\":\"partyinfrance\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/92a1a8baadc8edb75908400eb770e42f1cacc51799ca019260cdbb36ac3ab4f1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/92a1a8baadc8edb75908400eb770e42f1cacc51799ca019260cdbb36ac3ab4f1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/92a1a8baadc8edb75908400eb770e42f1cacc51799ca019260cdbb36ac3ab4f1?s=96&d=mm&r=g\",\"caption\":\"partyinfrance\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Commercializing Aptamers Part 6","description":"Explore the challenges of commercializing aptamers in our thought-provoking blog, as we dare to tackle a controversial subject. Read now.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/neoaptamers.com\/es\/commercializing-aptamers-part-6\/","og_locale":"es_ES","og_type":"article","og_title":"Commercializing Aptamers Part 6","og_description":"Explore the challenges of commercializing aptamers in our thought-provoking blog, as we dare to tackle a controversial subject. Read now.","og_url":"https:\/\/neoaptamers.com\/es\/commercializing-aptamers-part-6\/","og_site_name":"neoaptamers","article_published_time":"2021-10-13T09:31:17+00:00","article_modified_time":"2026-04-14T13:33:03+00:00","og_image":[{"width":1200,"height":600,"url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2021\/10\/zxzxx.png","type":"image\/png"}],"author":"partyinfrance","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"partyinfrance","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/neoaptamers.com\/commercializing-aptamers-part-6\/#article","isPartOf":{"@id":"https:\/\/neoaptamers.com\/commercializing-aptamers-part-6\/"},"author":{"name":"partyinfrance","@id":"https:\/\/neoaptamers.com\/#\/schema\/person\/34934951075d3d931c9216ed7f568fe6"},"headline":"Commercializing Aptamers Part 6","datePublished":"2021-10-13T09:31:17+00:00","dateModified":"2026-04-14T13:33:03+00:00","mainEntityOfPage":{"@id":"https:\/\/neoaptamers.com\/commercializing-aptamers-part-6\/"},"wordCount":542,"publisher":{"@id":"https:\/\/neoaptamers.com\/#organization"},"image":{"@id":"https:\/\/neoaptamers.com\/commercializing-aptamers-part-6\/#primaryimage"},"thumbnailUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2021\/10\/zxzxx.png","articleSection":["Aptamer commercialization"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/neoaptamers.com\/commercializing-aptamers-part-6\/","url":"https:\/\/neoaptamers.com\/commercializing-aptamers-part-6\/","name":"Commercializing Aptamers Part 6","isPartOf":{"@id":"https:\/\/neoaptamers.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/neoaptamers.com\/commercializing-aptamers-part-6\/#primaryimage"},"image":{"@id":"https:\/\/neoaptamers.com\/commercializing-aptamers-part-6\/#primaryimage"},"thumbnailUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2021\/10\/zxzxx.png","datePublished":"2021-10-13T09:31:17+00:00","dateModified":"2026-04-14T13:33:03+00:00","description":"Explore the challenges of commercializing aptamers in our thought-provoking blog, as we dare to tackle a controversial subject. Read now.","breadcrumb":{"@id":"https:\/\/neoaptamers.com\/commercializing-aptamers-part-6\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/neoaptamers.com\/commercializing-aptamers-part-6\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/neoaptamers.com\/commercializing-aptamers-part-6\/#primaryimage","url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2021\/10\/zxzxx.png","contentUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2021\/10\/zxzxx.png","width":1200,"height":600,"caption":"commercial aptamers part 6"},{"@type":"BreadcrumbList","@id":"https:\/\/neoaptamers.com\/commercializing-aptamers-part-6\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/neoaptamers.com\/"},{"@type":"ListItem","position":2,"name":"Commercializing Aptamers Part 6"}]},{"@type":"WebSite","@id":"https:\/\/neoaptamers.com\/#website","url":"https:\/\/neoaptamers.com\/","name":"Neoaptamers.com","description":"Neoventures Biotechnology Inc.","publisher":{"@id":"https:\/\/neoaptamers.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/neoaptamers.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/neoaptamers.com\/#organization","name":"NeoVentures Biotechnology Inc.","alternateName":"NVB","url":"https:\/\/neoaptamers.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/neoaptamers.com\/#\/schema\/logo\/image\/","url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2024\/07\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png","contentUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2024\/07\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png","width":500,"height":500,"caption":"NeoVentures Biotechnology Inc."},"image":{"@id":"https:\/\/neoaptamers.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/neoventures-biotechnology-inc-\/","https:\/\/www.reddit.com\/user\/NeoVenturesBiotech\/","https:\/\/www.youtube.com\/@neoaptamers7964"]},{"@type":"Person","@id":"https:\/\/neoaptamers.com\/#\/schema\/person\/34934951075d3d931c9216ed7f568fe6","name":"partyinfrance","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/92a1a8baadc8edb75908400eb770e42f1cacc51799ca019260cdbb36ac3ab4f1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/92a1a8baadc8edb75908400eb770e42f1cacc51799ca019260cdbb36ac3ab4f1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/92a1a8baadc8edb75908400eb770e42f1cacc51799ca019260cdbb36ac3ab4f1?s=96&d=mm&r=g","caption":"partyinfrance"}}]}},"_links":{"self":[{"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/posts\/1590","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/comments?post=1590"}],"version-history":[{"count":9,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/posts\/1590\/revisions"}],"predecessor-version":[{"id":1600,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/posts\/1590\/revisions\/1600"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/media\/1598"}],"wp:attachment":[{"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/media?parent=1590"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/categories?post=1590"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/neoaptamers.com\/es\/wp-json\/wp\/v2\/tags?post=1590"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}